ecancer

Results of KEYNOTE-054; melanoma patients treated with pembrolizumab.

Prof Alex Eggermont - Paris-Sud University, Paris, France

25 Apr 2018

Lenalidomide with rituximab for mantle cell lymphoma

Prof Jia Ruan - Weill Cornell Medicine and New York Presbyterian Hospital, New York, USA

11 Dec 2017

A biological perspective for personalising immunotherapies

Dr Tom Lillie - Head of European Clinical Development, MSD, London, UK

6 Dec 2017

Editor's Choice for November 2017

Prof Gordon McVie - Founding Editor, ecancer

4 Dec 2017

The promise of immunotherapy for elderly patients

Dr Alistair Greystoke - Newcastle University, Newcastle, UK

15 Nov 2017

Adoptive cell therapy for solid tumours

Dr Sophie Papa - Guy's Hospital, London, UK

18 Oct 2017

BRIM8: Vemurafenib in high risk melanoma patients

Dr Karl Lewis - University of Colorado Denver, Colorado, USA

11 Sep 2017

COMBI-AD: Dabrafenib plus trametinib in advanced melanoma

Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

11 Sep 2017

Expert commentary on melanoma immunotherapy latest

Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard

11 Sep 2017

Vemurafenib for high risk melanoma patients

Dr Karl Lewis - University of Colorado Denver, Colorado, USA

11 Sep 2017

Dabrafenib plus trametinib for stage III mutant melanoma

Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

11 Sep 2017

Nivolumab vs ipilimumab for high risk melanoma patients

Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA

11 Sep 2017

More from ecancer